Suppr超能文献

淋巴结比率可预测可切除的IV期下咽癌患者的复发及生存情况。

Lymph Node Ratio Predicts Recurrence and Survival for Patients with Resectable Stage 4 Hypopharyngeal Cancer.

作者信息

Lo Wu-Chia, Wu Chen-Tu, Wang Cheng-Ping, Yang Tsung-Lin, Lou Pei-Jen, Ko Jeng-Yuh, Chang Yih-Leong

机构信息

Department and Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei, 100, Taiwan.

Department of Otolaryngology, Far Eastern Memorial Hospital, Taipei, Taiwan.

出版信息

Ann Surg Oncol. 2017 Jun;24(6):1707-1713. doi: 10.1245/s10434-017-5770-1. Epub 2017 Jan 27.

Abstract

BACKGROUND

This study aimed to investigate the clinicopathologic prognostic predictors of stage 4 hypopharyngeal cancer and to extend the traditional tumor-node-metastasis classification system to advance its predictive ability.

METHODS

The study enrolled 120 patients with pathologically stage 4 hypopharyngeal cancer treated with pharyngolaryngectomy and neck dissection between 2001 and 2007.

RESULTS

The study showed a 5-year overall survival (OS) of 44.6%, a disease-specific survival (DSS) of 51.6%, and a disease-free survival (DFS) of 48% for all the patients. In the multivariate analysis, a lymph node (LN) ratio of 0.113 or higher was a significant poor prognostic factor for OS (hazard ratio [HR] 1.89; 95% confidence interval [CI] 1.17-3.05; p = 0.009), DSS (HR 2.17; 95% CI 1.29-3.64; p = 0.003), and DFS (HR, 2.24; 95% CI 1.12-4.52; p = 0.024) in stage 4 hypopharyngeal cancer. In addition, pretreatment neutrophil-lymphocyte ratio, lymphovascular invasion, and margin status also were predictors of survival outcomes. Furthermore, the study found that disease recurrence differed significantly between the patients with a LN ratio of 0.113 or higher (68.2%) and those with a LN ratio lower than 0.113 (39.5%) (p = 0.002).

CONCLUSIONS

A LN ratio of 0.113 or higher is a strong predictor of disease recurrence and survival for patients with stage 4 hypopharyngeal cancer.

摘要

背景

本研究旨在探究下咽癌4期的临床病理预后预测因素,并扩展传统的肿瘤-淋巴结-转移分类系统以提高其预测能力。

方法

本研究纳入了2001年至2007年间接受咽喉切除术和颈部清扫术治疗的120例病理分期为4期的下咽癌患者。

结果

研究显示,所有患者的5年总生存率(OS)为44.6%,疾病特异性生存率(DSS)为51.6%,无病生存率(DFS)为48%。在多因素分析中,淋巴结(LN)比率为0.113或更高是下咽癌4期患者OS(风险比[HR] 1.89;95%置信区间[CI] 1.17 - 3.05;p = 0.009)、DSS(HR 2.17;95% CI 1.29 - 3.64;p = 0.003)和DFS(HR 2.24;95% CI 1.12 - 4.52;p = 0.024)的显著不良预后因素。此外,治疗前中性粒细胞与淋巴细胞比率、淋巴管浸润和切缘状态也是生存结果的预测因素。此外,研究发现,LN比率为0.113或更高的患者(68.2%)与LN比率低于0.113的患者(39.5%)之间疾病复发存在显著差异(p = 0.002)。

结论

LN比率为0.113或更高是下咽癌4期患者疾病复发和生存的有力预测因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验